Biogen Notes Payable - Fair Value remained flat by 0.0% to $35.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 99.4%, from $5.47B to $35.00M. Over 3 years (FY 2020 to FY 2025), Notes Payable - Fair Value shows a downward trend with a -84.0% CAGR.
notes_payable_fair_value| Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.29B | $5.78B | $5.45B | $5.68B | $5.44B | $5.47B | $5.55B | $5.66B | $35.00M | $35.00M |
| QoQ Change | — | -8.0% | -5.8% | +4.3% | -4.3% | +0.6% | +1.5% | +2.0% | -99.4% | +0.0% |
| YoY Change | — | — | — | — | -13.5% | -5.4% | +1.9% | -0.4% | -99.4% | -99.4% |